BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 23, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2009

View Archived Issues

Dapagliflozin improves glycemic control in type 2 diabetes patients and in preclinical models

Read More

Celator completes enrollment in phase II clinical trial of CPX-351 in untreated AML

Read More

Signs of activity seen with PTC-299 in metastatic breast cancer patients

Read More

Trigone-specific injection of botulinum toxin type B improves idiopathic detrusor overactivity

Read More

Long-term improvements in signs of vaginal atrophy seen with ospemifene

Read More

Clinical data support safety and efficacy of S-equol in postmenopausal women

Read More

Nicorandil improves clinical outcomes in acute ST segment elevation myocardial infarction

Read More

Vaccine to treat cocaine dependence evaluated in phase IIb study / News in Context

Read More

Aquinox selects AQX-1125 as lead clinical candidate in SHIP program

Read More

Vanda and Novartis sign agreement for antipsychotic Fanapt in the U.S. and Canada

Read More

BioMimetic Therapeutics presents topline data from its Augment Bone Graft trial

Read More

Phytopharm reports results for Cogane in Parkinson's disease

Read More

EMEA grants orphan drug designation to ARQ-197 for soft tissue sarcoma

Read More

Myriad identifies IND candidate targeting IKK epsilon

Read More

Pieris reports preclinical development of VEGF antagonist PRS-050

Read More

OPKO Health acquires lead NK1 compounds from Schering-Plough

Read More

Newron returns rights to HF-0420 and pursues development of HF-0220

Read More

Depomed reports results of phase III trials of Serada for menopausal hot flashes

Read More

Raptor reports interim results from phase IIa clinical trial of DR cysteamine in NASH

Read More

Inovio Biomedical reports results on SynCon A/H1N1 influenza vaccine

Read More

CSL donates 3 million doses of pandemic influenza A (H1N1) vaccine to WHO

Read More

European Commission grants marketing authorization to Boehringer's Sifrol for PD

Read More

BMS describes NS5A protein inhibitors for the treatment of HCV infection

Read More

Servier claims dual nitric oxide donors and diuretic agents for treating hypertension

Read More

German scientists report EGFR and HER2 tyrosine kinase inhibitors for cancer treatment

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing